A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

16920HCRN-GU23-651-NCT07188896OpenA Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)HCRN GU23-651NCT07188896OtherAdultTreatmentIIKidneyAtkins, MichaelGeorgetown University Medical Center : Alan Zwart; Lombardi Comprehensive Cancer Center : Alan ZwartGenito-urinaryOncology GroupLombardi Comprehensive Cancer Center (LCCC)16795Alan ZwartAlan Zwartaz6@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>